Mixed findings from ICER on targeted immune modulators for RA
The USA’s Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of targeted immunomodulatory drugs for the treatment of rheumatoid arthritis (RA).
This Evidence Report will be the subject of the upcoming public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) on March 24, 2017.
The medicines cost-effectiveness body’ report evaluates the evidence on targeted immune modulators (TIMs), used alone or in combination with conventional disease-modifying anti-rheumatic drugs (DMARDs), as compared to conventional DMARDs alone. The review also includes an evaluation of two agents currently under regulatory review for this indication: sarilumab (Kevzara, from Sanofi [Euronext: SAN] and Regeneron [Nasdaq: REGN]) and baricitinib (Olumiant, from Eli Lilly [NYSE: LLY]).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze